Provided by Tiger Fintech (Singapore) Pte. Ltd.

CARSGEN-B

18.260
+0.6303.57%
Volume:313.50K
Turnover:5.61M
Market Cap:10.50B
PE:-11.55
High:18.280
Open:17.630
Low:17.190
Close:17.630
52wk High:25.600
52wk Low:5.920
Shares:575.00M
HK Float Shares:575.00M
Volume Ratio:1.68
T/O Rate:0.05%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.581
ROE:-42.45%
ROA:-19.52%
PB:9.96
PE(LYR):-11.55
PS:114.05

Loading ...

Hong Kong Stocks Move | CARSGEN-B (02171) Surges Over 9% in Early Trading as Company Presents Zewokilanse Injection Research at ESMO 2025

Stock News
·
Oct 20

CARsgen (2171) Presents Satri-cel Clinical Trial Results at ESMO 2025

Bulletin Express
·
Oct 20

CARsgen Presents Preliminary Results on Satri-Cel for Adjuvant Therapy of Pancreatic Cancer at Esmo Congress 2025

THOMSON REUTERS
·
Oct 20

CARsgen Therapeutics Announces Phase Ib Trial Results of Satri-cel for Pancreatic Cancer at ESMO Congress 2025

Reuters
·
Oct 20

High Growth Tech Stocks in Asia to Watch

Simply Wall St.
·
Oct 20

CARsgen Reports Promising Early Results for Allogeneic BCMA CAR-T Therapy in Relapsed Primary Plasma Cell Leukemia

Reuters
·
Oct 19

CARsgen Therapeutics announces positive phase 1 trial results for GPRC5D CAR T therapy CT071 in relapsed refractory multiple myeloma

Reuters
·
Oct 08

CARSGEN-B (02171): Research Updates on CT0596 to be Presented at 2025 ASH Annual Meeting

Stock News
·
Oct 06

CARsgen Therapeutics to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress

Reuters
·
Oct 06

CARSGEN-B (02171): Non-executive Director Kwok Ping-sum Passes Away

Stock News
·
Sep 24

CARsgen Therapeutics Announces Passing of Non-Executive Director Bingsen Guo; Board Extends Condolences and Pays Tribute to His Contributions

Reuters
·
Sep 24

CARSGEN-B (02171) Presents Updated Research Results for Seicarez® at 22nd IMS Annual Meeting

Stock News
·
Sep 18

HK Movers | Biotech Stocks Surge With Cutia Therapeutics up 14%

Tiger Newspress
·
Aug 29

Stock Track | CARsgen Therapeutics Soars 5.10% on Narrowed Losses and Strong Interim Results

Stock Track
·
Aug 15

Stock Track | CARsgen Therapeutics Soars 5.10% on Strong H1 2025 Results and Product Pipeline Progress

Stock Track
·
Aug 15

CARsgen Therapeutics' H1 Loss Narrows Year-on-Year

MT Newswires Live
·
Aug 15

Press Release: CARsgen Therapeutics Announces 2025 Interim Results

Dow Jones
·
Aug 15

CARSGEN-B (02171) Reports Interim Results with Net Loss of 75.48 Million Yuan, Narrowing 78.53% Year-over-Year

Stock News
·
Aug 14

CARsgen Therapeutics Holdings H1 Net Income RMB -75 Million

THOMSON REUTERS
·
Aug 14

CARsgen Therapeutics Holdings H1 Adjusted Net Income RMB -72 Million

THOMSON REUTERS
·
Aug 14